
ExcepGen Inc - RNA therapeutics for longevity



Stage
Seed stage start-up
Area
Vaccines and RNA therapeutics
Status
Ongoing
Patent Status
Portfolio of patent applications submitted
Background
Severe viral infections can induce immune dysfunction and chronic inflammation, mimicking the symptoms of aging and often persisting even after the pathogen has been cleared. The NIH's National Institute on Aging emphasizes the serious threat that viruses, like influenza and COVID-19, pose to elderly adults. To combat these health risks, ExcepGen's RNAx platform focuses on enhancing the effectiveness of RNA cargo, thereby promoting the production of protective proteins within the body. Their primary project is the development of a universal pan-flu vaccine, utilizing the strengths of self-amplifying RNA (saRNA), while mitigating its inflammatory side effects, a breakthrough with significant potential in enhancing longevity.
Aims, Hypothesis & Results
Aims: ExcepGen's primary objective is to exploit the potential of its RNAx platform to develop an advanced generation of vaccines. The central aim is to construct a universal pan-flu vaccine that harnesses the advantages of self-amplifying RNA (saRNA) while minimizing the associated inflammatory drawbacks.
Hypothesis: ExcepGen hypothesizes that by using RNAx to modulate signals within cells, it can enhance the effectiveness of RNA cargo. This process is expected to result in increased protein production and subsequently greater protection against severe viral infections, offering hope for aging populations.
Results: Preliminary studies have shown promising results. Experiments using saRNAx produced a 400% boost in cargo expression in vivo in mice, compared to standard saRNA. In innate-immune-competent human BJ cells, saRNAx resulted in up to 2600% improvement in cargo expression. Furthermore, saRNAx majorly reduced and, in some cases, completely prevented harmful inflammatory cytokine release, supporting the hypothesis of the project. Based on these encouraging results, ExcepGen is proceeding with the development of a universal pan-flu vaccine, among other pipeline products.
Timeline
Pre-Clinical Studies: In-vivo PoC for universal influence Vx + self amplifying RNA (saRNA) in an animal model
Required Funding: $100,000
Status: Ongoing
Duration: Ongoing
VitaDAO Board Evaluation Writeup
ExcepGen's project received positive feedback and was praised for its advanced state, ample data, strong partnerships, and significant funding. The reviewers recommended funding, acknowledging the platform's potential for various therapeutic and prophylactic applications. They recognized the strong connection between flu vaccines and VitaDAO's mission, given the impact of flu on elderly populations. ExcepGen's technology's applicability to mRNA vaccines and potential for partnerships were noted, as was the strength of the team and investors.

Non Consectetur Necessitatibus
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

Eum Harum Asperiores Id
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

Ex Temporibus Perferendis
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

Dolorum Quia
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

Earum Est Dolorem
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

Culpa Possimus
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

Aperiam Et Quis Et
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

Voluptas Quam Sapiente
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

Aut Accusantium Ut
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

Nisi
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
The vote has passed, the decision is made: ExceptGen will be the first company sourced by VitaDAO’s strategic partner Pfizer Ventures to be funded by DeSci. This historic moment needs to be celebrated properly!
Discover more projects & initiatives

Humanity
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

Matrix Bio
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.

BE Therapeutics - Brain Tissue Replacement
The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.

Discovering Novel Autophagy Activators
Autophagy - the mechanism to recycle cellular components - becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds with the aim of restoring autophagy function to aged cells.